Cargando…

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

BACKGROUND: AGITG DOCTOR was a randomised phase 2 trial of pre-operative cisplatin, 5 fluorouracil (CF) followed by docetaxel (D) with or without radiotherapy (RT) based on poor early response to CF, detected via PET, for resectable oesophageal adenocarcinoma. This study describes PROs over 2 years....

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercieca-Bebber, R., Barnes, E. H., Wilson, K., Samoon, Z., Walpole, E., Mai, T., Ackland, S., Burge, M., Dickie, G., Watson, D., Leung, J., Wang, T., Bohmer, R., Cameron, D., Simes, J., Gebski, V., Smithers, M., Thomas, J., Zalcberg, J., Barbour, A. P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922838/ https://www.ncbi.nlm.nih.gov/pubmed/35291965 http://dx.doi.org/10.1186/s12885-022-09270-4

Ejemplares similares

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
por: Leong, Trevor, et al.
Publicado: (2015)

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank
por: Lonie, James M., et al.
Publicado: (2023)

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
por: Lam, Lyn Ley, et al.
Publicado: (2023)

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
por: Tebbutt, N C, et al.
Publicado: (2010)

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
por: Zhang, Jiahui, et al.
Publicado: (2022)

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy
por: M. Naeini, Marjan, et al.
Publicado: (2023)

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer
por: Sjoquist, Katrin M., et al.
Publicado: (2022)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
por: Oar, Andrew, et al.
Publicado: (2021)

SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial
por: Jameson, Michael B., et al.
Publicado: (2019)

The GOFURTGO Study: AGITG Phase II Study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer
por: Goldstein, D, et al.
Publicado: (2012)

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
por: Price, T J, et al.
Publicado: (2015)

The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training
por: Mercieca-Bebber, Rebecca, et al.
Publicado: (2017)

A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer
por: Wilson, Michelle K., et al.
Publicado: (2018)

The importance of patient-reported outcomes in clinical trials and strategies for future optimization
por: Mercieca-Bebber, Rebecca, et al.
Publicado: (2018)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
por: Day, F L, et al.
Publicado: (2011)

Laparoscopic fundoplication versus laparoscopic Roux-en-Y gastric bypass for gastro-oesophageal reflux disease in obese patients: protocol for a randomized clinical trial
por: Frankel, Adam, et al.
Publicado: (2022)

Challenges of international oncology trial collaboration—a call to action
por: Tang, Monica, et al.
Publicado: (2019)

Doctors vs. Tailors
Publicado: (1857)

Patient-Reported Outcome (PRO) Assessment in Clinical Trials: A Systematic Review of Guidance for Trial Protocol Writers
por: Calvert, Melanie, et al.
Publicado: (2014)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
por: Siu, Ho Wai Derrick, et al.
Publicado: (2021)

A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: implications for generalisability and clinical practice
por: Mercieca-Bebber, Rebecca, et al.
Publicado: (2017)

Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020)
por: Farrell, Rhonda, et al.
Publicado: (2021)

Individual patient oesophageal cancer 3D models for tailored treatment
por: Saunders, John H., et al.
Publicado: (2016)

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer
por: Ackland, S P, et al.
Publicado: (2005)

Systematic Evaluation of the Patient-Reported Outcome (PRO) Content of Clinical Trial Protocols
por: Kyte, Derek, et al.
Publicado: (2014)

Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III‐trial AGITG‐MAX
por: van Dijk, Erik, et al.
Publicado: (2022)

Patient, client, consumer, survivor or other alternatives? A scoping review of preferred terms for labelling individuals who access healthcare across settings
por: Costa, Daniel S J, et al.
Publicado: (2019)

Residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer: locations undetected by endoscopic biopsies in the preSANO trial
por: van der Wilk, B. J., et al.
Publicado: (2020)

Improving the patient-reported outcome sections of clinical trial protocols: a mixed methods evaluation of educational workshops
por: King, Madeleine T., et al.
Publicado: (2022)

Driving developments in UK oesophageal radiotherapy through the SCOPE trials
por: Gwynne, S., et al.
Publicado: (2019)

Study protocol for the nutritional route in oesophageal resection trial: a single-arm feasibility trial (NUTRIENT trial)
por: Weijs, Teus J, et al.
Publicado: (2014)

Primary care randomised controlled trial of a tailored interactive website for the self-management of respiratory infections (Internet Doctor)
por: Little, Paul, et al.
Publicado: (2016)

Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review
por: Mercieca-Bebber, Rebecca, et al.
Publicado: (2016)

Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy
por: Wills, Lucy, et al.
Publicado: (2017)

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer
por: Lee, C K, et al.
Publicado: (2010)

Efficacy of laparoscopic fundoplication in patients with chronic cough and gastro-oesophageal reflux
por: Frankel, Adam, et al.
Publicado: (2022)

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone
por: Lee, Chee Khoon, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_eg0j4hfg2g828mnkopfd8t08fq